Daniel Catenacci, MD - 2010 Young Investigator Award
“The Role of RON EMST1R in gastroesophageal adenocarcinoma”
Awarded a $75,000 2010 Young Investigator Award
Gastroesophageal adenocarcinoma (GEC) remains the fourth most common malignancy worldwide and the second most common cause of death worldwide, with some types having an estimated 350% increase in incidence in the United States in the last two to three decades. Most GECs present at an advanced stage, overall 5-year survival is poor, and effective treatments are lacking. RON (MST1R) receptor tyrosine kinase plays an important role in the progression of GEC, especially in the setting of MET coexpression, and is an important prognostic marker and molecular therapeutic target. The goal of this proposal is to determine the RON expression and gene alteration found in GEC. Expression patterns found will be prognostic, correlating with survival outcomes and other clinical parameters. Furthermore, studies will be performed to discover the biological and biochemical effects of specific inhibitors against RON in GEC. These investigations will ultimately lead to the development of optimal strategies for the use of RON inhibitors and how they can be combined with other inhibitors and chemotherapy protocols to further enhance anti-neoplastic effects.
The Cancer Research Foundation has focused attention on cancer and raised money for life-giving research. We...pay tribute to the scientists who have dedicated themselves to finding a cure and to meet the young researchers who are the next generation of fighters against this disease. The message we send today is that those who suffer from cancer are not alone and that together we can work toward a solution."Richard M. Daley
Mayor, City of Chicago
May 20, 1997